Atrial Fibrillation Management Guidelines

Initial Assessment and Management

The American College of Cardiology recommends immediately assessing for hemodynamic instability by checking for shock, hypotension, acute heart failure, angina, or myocardial infarction in patients with atrial fibrillation 1, 2
Identify reversible causes including thyroid dysfunction, electrolyte abnormalities, alcohol consumption, and infection in patients with atrial fibrillation 1, 2
Determine the duration of atrial fibrillation if possible, as episodes <48 hours versus ≥48 hours/unknown duration require different anticoagulation approaches before cardioversion 1

The American College of Cardiology recommends performing immediate electrical cardioversion without waiting for anticoagulation in hemodynamically unstable patients with atrial fibrillation 1, 2
Use initial energy of 200 J or greater with either monophasic or biphasic waveforms for electrical cardioversion in patients with atrial fibrillation 2
Administer heparin concurrently via IV bolus followed by continuous infusion targeting aPTT 1.5-2 times control in patients with atrial fibrillation undergoing cardioversion 1, 2

The American College of Cardiology recommends using intravenous beta-blockers or non-dihydropyridine calcium channel blockers as first-line agents for acute rate control in patients with atrial fibrillation 3, 1
Measure heart rate both at rest and during exercise, targeting physiological range in patients with atrial fibrillation 3, 4, 5
Avoid using beta-blockers or calcium channel blockers in patients with accessory pathway conduction, such as Wolff-Parkinson-White syndrome 3, 1

The American College of Cardiology recommends administering antithrombotic therapy to all patients with atrial fibrillation except those with lone atrial fibrillation (age <60 years, no heart disease) 3, 4, 5, 1
Use oral anticoagulation with target INR 2-3 for at least 3-4 weeks before and after cardioversion in patients with atrial fibrillation lasting >48 hours or unknown duration 1

The European Heart Journal reports that rate control and rhythm control strategies show no significant difference in all-cause mortality, cardiovascular mortality, or stroke rates in most patients with atrial fibrillation 6
Use beta-blockers or calcium channel antagonists in patients with preserved ejection fraction, and beta-blockers and/or digoxin in patients with reduced ejection fraction for rate control in atrial fibrillation 2
Target physiological heart rate range at rest and during exercise in patients with atrial fibrillation 3, 4, 5

Never delay electrical cardioversion in hemodynamically unstable patients while waiting for anticoagulation in patients with atrial fibrillation 1, 2
Never attempt elective cardioversion without appropriate anticoagulation in patients with AF lasting >48 hours or unknown duration 1, 2
Never omit anticoagulation in high-risk patients based on bleeding concerns without formal risk-benefit assessment in patients with atrial fibrillation 1
Never use digoxin as the sole agent for rate control in paroxysmal atrial fibrillation 1, 2
Never fail to identify and treat reversible causes, such as thyroid dysfunction, electrolyte abnormalities, alcohol consumption, and infection in patients with atrial fibrillation 1, 2
Never use beta-blockers or calcium channel blockers in patients with accessory pathway conduction, such as Wolff-Parkinson-White syndrome 3, 1